A global panel of experts discusses several recent data updates on the role of immunotherapy in non-small cell lung cancer (NSCLC) and their impact on clinical practice.
December 16th 2022
Shared perspectives on the emerging strategies for the management of non–small cell lung cancer following the identification of KRAS/STK11, or KRAS/KEAP1 mutations.
December 23rd 2022
Before closing out their discussion on IO therapy in non–small cell lung cancer, Melissa Johnson, MD, and Joshua Sabari, MD, identify treatment strategies in the setting of concomitant KRAS/p53 mutation.